logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Return

Micrococcin P2 Targets Clostridioides difficile

delete2022-07-11
delete5
PRE
AI
Y
Young‐Jin Son
Y
Young‐Rok Kim
S
Sang‐Hun Oh
S
Sungji Jung
M
Marco A. Ciufolini
H
Hee-Jong Hwang *
J
Jin‐Hwan Kwak *
H
Hyunjoo Pai *
DOI：10.1021/acs.jnatprod.2c00120delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Clostridioides difficile infection is a global public health threat. Extensive in vitro assays using clinical isolates have identified micrococcin P2 (MP2, 1) as a particularly effective anti C. difficile agent. MP2 possesses a mode of action that differs from other antibiotics and pharmacokinetic properties that render it especially promising. Its time-kill studies have been investigated using hypervirulent C. difficile ribotype 027. DSS (dextran sulfate sodium)-induced in vivo mouse studies with that strain indicate that 1 is better than vancomycin and fidaxomicin. Thus, micrococcin P2 is a valuable platform to be exploited for the development of new anti-C. difficile antibiotics.
Keywords:
INFLAMMATORY-BOWEL-DISEASE
ANTIBIOTIC-RESISTANCE
INFECTION
FIDAXOMICIN
VANCOMYCIN
TOXIN
ANTIBACTERIAL
OPTIMIZATION
MICROBIOME
RECURRENCE

Journal

Journal of Natural Products cover
Journal of Natural Products
IF:
3.6
Papers:
1.2W
Citations:
2.9W

Organization

H
hanyang university
Scholars:
2.8W
Papers: 2.7W
Citations: 36
S
seoul national university (snu)
Scholars:
7.1W
Papers: 6.6W
Citations: 86
U
University of British Columbia
Scholars:
6.9W
Papers: 6.1W
Citations: 8.6W
researcher View more organizations